1. 5 FDA approval decisions to watch for in Q4 — Can general practitioners survive COVID-19? — 7 former FDA commissioners write opinion column lamenting White House's treatment of agency — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Time to Sell Mylan Amid EpiPen Controversy

Discussion in 'Pharma/Biotech Companies - In the News' started by RobertPhillips900, Sep 6, 2016 at 2:45 PM.

  1. RobertPhillips900

    Aug 29, 2016
    Likes Received:
    Mylan, famously known as the maker of EpiPen, grabbed our attention in the past few weeks in a very negative way. This is because of the sudden increase in the price of EpiPens. Unbelievable, but yes with almost 500% increase since 2007, today the drug- a life-saving treatment for allergic reactions-costs almost $608. And the company fails at providing any valid reason for this jump in price.

    Because of all this, office of Attorney General Eric Schneiderman launched an antitrust probe of the EipPen contracts. Due to this new issue, Mylan shares are trading in red. Analysts rate this stock ‘Sell’.

  2. anonymous

    anonymous Guest

    So why is she CEO? Huge scandal that ended with the severed heads of several from WVU who somehow gave her a Masters Degree she never finished, then after making multimillions in bonus during the years of epipen gouging she lies to congress, and KEEPS HER JOB!!!!????